These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 6946675)
1. Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route. Løber J; Mouridsen HT; Salimtschik M; Johansson E Acta Obstet Gynecol Scand Suppl; 1981; 101():71-4. PubMed ID: 6946675 [TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes. Salimtschik M; Mouridsen HT; Loeber J; Johansson E Cancer Chemother Pharmacol; 1980; 4(4):267-9. PubMed ID: 7438329 [TBL] [Abstract][Full Text] [Related]
3. Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study. Hesselius I; Johansson ED Acta Obstet Gynecol Scand Suppl; 1981; 101():65-70. PubMed ID: 6795891 [TBL] [Abstract][Full Text] [Related]
4. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma. Laatikainen T; Nieminen U; Adlercreutz H Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965 [TBL] [Abstract][Full Text] [Related]
5. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117 [TBL] [Abstract][Full Text] [Related]
6. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations. Stockdale AD; Chapman D; Mould GP; Rostom AY Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052 [TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. Johansson ED; Johansen PB; Rasmussen SN Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):311-7. PubMed ID: 2943134 [TBL] [Abstract][Full Text] [Related]
8. The bioavailability of an orally administered medroxyprogesterone acetate suspension. Antal EJ; Gillespie WR; Albert KS Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):257-9. PubMed ID: 6222996 [TBL] [Abstract][Full Text] [Related]
9. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration]. Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of different doses of Depo Provera. Fotherby K; Koetsawang S; Mathrubutham M Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351 [TBL] [Abstract][Full Text] [Related]
12. Plasma levels of medroxyprogesterone acetate (MPA), estradiol and progesterone in the rhesus monkey after intramuscular adminstration of Depo-Provera. Mora G; Johansson ED Contraception; 1976 Sep; 14(3):343-50. PubMed ID: 824097 [TBL] [Abstract][Full Text] [Related]
13. Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients. Pannuti F; Camaggi CM; Strocchi E; Giovannini M; Di Marco AR; Costanti B Cancer Treat Rep; 1982 Dec; 66(12):2043-9. PubMed ID: 7139647 [TBL] [Abstract][Full Text] [Related]
14. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer. Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689 [TBL] [Abstract][Full Text] [Related]
15. Radioimmunoassay for serum medroxyprogesterone acetate in Thai women receiving injectable DMPA contraceptive. Werawatgoompa S; Pongpradit T; Leepipatpaiboon S; Sukanthanak A Contraception; 1979 Oct; 20(4):319-27. PubMed ID: 509958 [TBL] [Abstract][Full Text] [Related]
16. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524 [TBL] [Abstract][Full Text] [Related]
17. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses. Wikström A; Green B; Johansson ED Acta Obstet Gynecol Scand; 1984; 63(2):163-8. PubMed ID: 6233840 [TBL] [Abstract][Full Text] [Related]
18. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology. Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441 [TBL] [Abstract][Full Text] [Related]
19. Treatment of breast cancer with medroxyprogesterone acetate. Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126 [TBL] [Abstract][Full Text] [Related]
20. Radioimmunoassay for medroxyprogesterone acetate (Provera) using the 11alpha-hydroxy succinyl conjugate. Royer ME; Ko H; Campbell JA; Murray HC; Evans JS; Kaiser DG Steroids; 1974 May; 23(5):713-30. PubMed ID: 4365969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]